Ivacaftor Patent Expiration
Ivacaftor is used for treating Cystic Fibrosis by targeting specific CFTR mutations with Ivacaftor treatment. It was first introduced by Vertex Pharmaceuticals Inc
Ivacaftor Patents
Given below is the list of patents protecting Ivacaftor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kalydeco |
US10272046 (Pediatric) | Pharmaceutical composition and administrations thereof | Aug 27, 2033 | Vertex Pharms Inc |
| Kalydeco |
US11147770 (Pediatric) | Pharmaceutical composition and administrations thereof | Aug 27, 2033 | Vertex Pharms Inc |
| Kalydeco |
US11752106 (Pediatric) | Pharmaceutical composition and administrations thereof | Aug 27, 2033 | Vertex Pharms Inc |
| Kalydeco |
US12214083 (Pediatric) | Pharmaceutical composition and administrations thereof | Aug 27, 2033 | Vertex Pharms Inc |
| Kalydeco |
US8883206 (Pediatric) | Pharmaceutical composition and administrations thereof | Aug 27, 2033 | Vertex Pharms Inc |
| Kalydeco | US10272046 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Kalydeco | US11147770 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Kalydeco | US11752106 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Kalydeco | US12214083 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Kalydeco | US8883206 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Kalydeco |
US10646481 (Pediatric) | Pharmaceutical composition and administrations thereof | Feb 13, 2030 | Vertex Pharms |
| Kalydeco |
US10646481 (Pediatric) | Pharmaceutical composition and administrations thereof | Feb 13, 2030 | Vertex Pharms Inc |
| Kalydeco |
US11564916 (Pediatric) | Pharmaceutical composition and administrations thereof | Feb 13, 2030 | Vertex Pharms |
| Kalydeco |
US11564916 (Pediatric) | Pharmaceutical composition and administrations thereof | Feb 13, 2030 | Vertex Pharms Inc |
| Kalydeco |
US12458635 (Pediatric) | Pharmaceutical Composition And Administrations Thereof | Feb 13, 2030 | Vertex Pharms |
| Kalydeco |
US12458635 (Pediatric) | Pharmaceutical Composition And Administrations Thereof | Feb 13, 2030 | Vertex Pharms Inc |
| Kalydeco | US10646481 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms |
| Kalydeco | US10646481 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Kalydeco | US11564916 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms |
| Kalydeco | US11564916 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Kalydeco | US12458635 | Pharmaceutical Composition And Administrations Thereof | Aug 13, 2029 | Vertex Pharms |
| Kalydeco | US12458635 | Pharmaceutical Composition And Administrations Thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Kalydeco |
US8324242 (Pediatric) | Modulators of ATP-binding cassette transporters | Feb 05, 2028 | Vertex Pharms |
| Kalydeco |
US8324242 (Pediatric) | Modulators of ATP-binding cassette transporters | Feb 05, 2028 | Vertex Pharms Inc |
| Kalydeco |
US7495103 (Pediatric) | Modulators of ATP-binding cassette transporters | Nov 20, 2027 | Vertex Pharms |
| Kalydeco |
US7495103 (Pediatric) | Modulators of ATP-binding cassette transporters | Nov 20, 2027 | Vertex Pharms Inc |
| Kalydeco | US8324242 | Modulators of ATP-binding cassette transporters | Aug 05, 2027 | Vertex Pharms |
| Kalydeco | US8324242 | Modulators of ATP-binding cassette transporters | Aug 05, 2027 | Vertex Pharms Inc |
| Kalydeco |
US8410274 (Pediatric) | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Jun 28, 2027 | Vertex Pharms |
| Kalydeco |
US8410274 (Pediatric) | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Jun 28, 2027 | Vertex Pharms Inc |
| Kalydeco |
US8754224 (Pediatric) | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Jun 28, 2027 | Vertex Pharms |
| Kalydeco |
US8754224 (Pediatric) | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Jun 28, 2027 | Vertex Pharms Inc |
| Kalydeco |
US9670163 (Pediatric) | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Jun 28, 2027 | Vertex Pharms |
| Kalydeco |
US9670163 (Pediatric) | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Jun 28, 2027 | Vertex Pharms Inc |
| Kalydeco | US7495103 | Modulators of ATP-binding cassette transporters | May 20, 2027 | Vertex Pharms |
| Kalydeco | US7495103 | Modulators of ATP-binding cassette transporters | May 20, 2027 | Vertex Pharms Inc |
| Kalydeco |
US8354427 (Pediatric) | Modulators of ATP-binding cassette transporters | Jan 06, 2027 | Vertex Pharms |
| Kalydeco |
US8354427 (Pediatric) | Modulators of ATP-binding cassette transporters | Jan 06, 2027 | Vertex Pharms Inc |
| Kalydeco | US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms |
| Kalydeco | US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Kalydeco | US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms |
| Kalydeco | US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Kalydeco | US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms |
| Kalydeco | US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Kalydeco | US8354427 | Modulators of ATP-binding cassette transporters |
Jul 06, 2026
(Expired) | Vertex Pharms |
| Kalydeco | US8354427 | Modulators of ATP-binding cassette transporters |
Jul 06, 2026
(Expired) | Vertex Pharms Inc |
| Kalydeco | US8629162 | Modulators of ATP-binding cassette transporters |
Jun 24, 2025
(Expired) | Vertex Pharms |
| Kalydeco | US8629162 | Modulators of ATP-binding cassette transporters |
Jun 24, 2025
(Expired) | Vertex Pharms Inc |
Ivacaftor's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Ivacaftor:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
